Homologous recombination deficiency (HRD)-positive ovarian cancer

Homologous recombination deficiency (HRD)-positive ovarian cancer refers to epithelial ovarian, fallopian tube, or primary peritoneal malignancy characterized by an inability to accurately repair DNA double-strand breaks via the homologous recombination repair pathway This clinical state affects adult females and is defined by the presence of deleterious germline or somatic mutations in pathway genes, predominantly BRCA1 or BRCA2, or by measurable signatures of genomic instability such as loss o...

Homologous recombination deficiency (HRD)-positive ovarian cancer refers to epithelial ovarian, fallopian tube, or primary peritoneal malignancy characterized by an inability to accurately repair DNA double-strand breaks via the homologous recombination repair pathway

This clinical state affects adult females and is defined by the presence of deleterious germline or somatic mutations in pathway genes, predominantly BRCA1 or BRCA2, or by measurable signatures of genomic instability such as loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions The resulting impairment forces malignant cells to rely on alternative, error-prone repair pathways, creating profound genomic instability that renders the tumor hypersensitive to DNA-dama...

This clinical state affects adult females and is defined by the presence of deleterious germline or somatic mutations in pathway genes, predominantly BRCA1 or BRCA2, or by measurable signatures of genomic instability such as loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions

The resulting impairment forces malignant cells to rely on alternative, error-prone repair pathways, creating profound genomic instability that renders the tumor hypersensitive to DNA-damaging agents

Clinically, HRD status serves as a predictive biomarker for synthetic lethality and superior therapeutic vulnerability to poly (ADP-ribose) polymerase inhibitors and platinum-based therapies

Clinically, HRD status serves as a predictive biomarker for synthetic lethality and superior therapeutic vulnerability to poly (ADP-ribose) polymerase inhibitors and platinum-based therapies

Clinically, HRD status serves as a predictive biomarker for synthetic lethality and superior therapeutic vulnerability to poly (ADP-ribose) polymerase inhibitors and platinum-based therapies